Antisense Oligonucleotide Shows Potential in Dravet Syndrome

(MedPage Today) -- Multiple doses of STK-001, an investigational antisense oligonucleotide to treat Dravet syndrome, were well tolerated and showed trends toward fewer seizures, interim analyses of phase I/IIa trial data showed.
In a combined...